The Molecular and Cellular Basis of Tumor Rejection After Vaccination With Mammary Adenocarcinoma Cells Transduced With the MHC Class II Transactivator CIITA

被引：0
|
作者：
Lorenzo Mortara
Paola Castellani
Raffaella Meazza
Giovanna Tosi
Andrea De Lerma Barbaro
Francesco A Procopio
Luciano Zardi
Silvano Ferrini
Roberto S Accolla
机构：
[1] University of Insubria,Department of Clinical and Biological Sciences, School of Medicine
[2] Istituto Nazionale per la Ricerca sul Cancro,Laboratory of Cellular Biology
[3] Istituto Nazionale per la Ricerca sul Cancro,Laboratory of Immunopharmacology
[4] Advanced Biotechnology Center,Philogen
来源：
Retrovirology | / 2卷
关键词：
ELISPOT Assay; Vaccination Protocol; Massive Necrosis; Mammary Adenocarcinoma Cell; Syngeneic Recipient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity
    Rickard, Steve
    Ono, Santa Jeremy
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2008, 85 (03) : 147 - 154
  • [32] Human glioblastoma tumor cells process myelin autoantigen for presentation to antigen-specific class II-restricted CD4+T cells:: Two distinct MHC class II transactivator (CIITA) promoters are utilized for IFNγ-inducible CIITA expression
    Soos, JM
    Krieger, J
    King, CL
    Stuve, O
    Nelson, PA
    Zamvil, SS
    NEUROLOGY, 2000, 54 (07) : A35 - A36
  • [33] Selective modulation of MHC class II chaperons by a novel IFN-γ-inducible class II transactivator variant in lung adenocarcinoma A549 cells
    Chiu, Bau-Lin
    Li, Chia-Hsuan
    Chang, Chien-Chung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 440 (01) : 190 - 195
  • [34] Class II Major Histocompatibility Complex Transactivator (CIITA) Knockdown Prevents Immune Rejection of Allogeneic Bone Marrow Stem Cells in Cardiac Regeneration
    Ludke, Ana
    Huang, Xi-Ping
    Dhingra, Sanjiv
    Guo, Jian
    Sun, Zhuo
    Li, Shu-hong
    Weisel, Richard D.
    Li, Ren-Ke
    CIRCULATION, 2014, 130
  • [35] Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription -: Implication of CIITA in tumor and metastasis development
    Shi, B
    Vinyals, A
    Alia, P
    Broceño, C
    Chen, FS
    Adrover, M
    Gelpi, C
    Price, JE
    Fabra, A
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (04): : 544 - 562
  • [36] Two distinct MHC class II transactivator (CIITA) promoters are utilized for IFNg-inducible CIITA expression by human glioblastoma (GBM) cells that process myelin autoantigen for presentation to CD4+T cells
    Soos, JM
    Krieger, J
    King, CL
    Stuve, O
    Nelson, PA
    Zamvil, SS
    FASEB JOURNAL, 2000, 14 (06): : A1195 - A1195
  • [37] Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells
    Chou, SD
    Khan, ANH
    Magner, WJ
    Tomasi, TB
    INTERNATIONAL IMMUNOLOGY, 2005, 17 (11) : 1483 - 1494
  • [38] REJECTION OF MOUSE SARCOMA-CELLS AFTER TRANSFECTION OF MHC CLASS-II GENES
    OSTRANDROSENBERG, S
    THAKUR, A
    CLEMENTS, V
    JOURNAL OF IMMUNOLOGY, 1990, 144 (10): : 4068 - 4071
  • [39] CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine
    Accolla, Roberto S.
    Ramia, Elise
    Tedeschi, Alessandra
    Forlani, Greta
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [40] CIITA- driven MHC class II expressing tumor cells can efficiently prime naive CD4C TH cells in vivo and vaccinate the host against parental MHC- II- negative tumor cells
    Eddine, Farah Bou Nasser
    Forlani, Greta
    Lombardo, Letizia
    Tedeschi, Alessandra
    Tosi, Giovanna
    Accolla, Roberto S.
    ONCOIMMUNOLOGY, 2017, 6 (01):
12345